NCT04408937View on ClinicalTrials.gov

The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor.

PHASE1CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

May 29, 2020

Primary Completion Date

November 4, 2020

Study Completion Date

November 4, 2020

Conditions
Liver Disease
Interventions
DRUG

triopifexor

Tropifexor as a dry blend in hard gelatin capsules for oral administration

DRUG

Placebo

Placebo capsules for oral administration

Trial Locations (10)

28557

Novartis Investigative Site, Morehead City

32503

Novartis Investigative Site, Pensacola

35758

Novartis Investigative Site, Madison

37076

Novartis Investigative Site, Hermitage

37920

Novartis Investigative Site, Knoxville

46635

Novartis Investigative Site, South Bend

78215

Novartis Investigative Site, San Antonio

92118

Novartis Investigative Site, Coronado

33014-3616

Novartis Investigative Site, Miami

75208-2312

Novartis Investigative Site, Dallas

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY